JP6883049B2 - アミノチアゾール化合物及びその使用 - Google Patents
アミノチアゾール化合物及びその使用 Download PDFInfo
- Publication number
- JP6883049B2 JP6883049B2 JP2018560435A JP2018560435A JP6883049B2 JP 6883049 B2 JP6883049 B2 JP 6883049B2 JP 2018560435 A JP2018560435 A JP 2018560435A JP 2018560435 A JP2018560435 A JP 2018560435A JP 6883049 B2 JP6883049 B2 JP 6883049B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- cycloalkyl
- halo
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Cc(c(C)c1)ccc1C1=C*=*[U]1 Chemical compound Cc(c(C)c1)ccc1C1=C*=*[U]1 0.000 description 3
- TYCZVMVIYLXPSX-UHFFFAOYSA-N CCc1cc(NC(Nc(ccc(-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)c2)c2F)=O)n[o]1 Chemical compound CCc1cc(NC(Nc(ccc(-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)c2)c2F)=O)n[o]1 TYCZVMVIYLXPSX-UHFFFAOYSA-N 0.000 description 2
- AAZWOYHDKCZELR-UHFFFAOYSA-N CC(C)(C)c1cc(NC(Nc(c(C)c2)ccc2-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)=O)n[o]1 Chemical compound CC(C)(C)c1cc(NC(Nc(c(C)c2)ccc2-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)=O)n[o]1 AAZWOYHDKCZELR-UHFFFAOYSA-N 0.000 description 1
- ZQIYCQCKHPAVMM-UHFFFAOYSA-N CCC1=CC(NC(Nc(cc2)ccc2-c2cnc(Nc3cc(OCCN4CCOCC4)ncn3)[s]2)=O)=[N+]1[O-] Chemical compound CCC1=CC(NC(Nc(cc2)ccc2-c2cnc(Nc3cc(OCCN4CCOCC4)ncn3)[s]2)=O)=[N+]1[O-] ZQIYCQCKHPAVMM-UHFFFAOYSA-N 0.000 description 1
- DKMMDRNAHZQBOR-UHFFFAOYSA-N CCc1cc(NC(Nc(cc2)ccc2-c2cnc(NC(N=CN3)=CC3N3CCN(CCF)CC3)[s]2)=O)n[o]1 Chemical compound CCc1cc(NC(Nc(cc2)ccc2-c2cnc(NC(N=CN3)=CC3N3CCN(CCF)CC3)[s]2)=O)n[o]1 DKMMDRNAHZQBOR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291667P | 2016-02-05 | 2016-02-05 | |
| US62/291,667 | 2016-02-05 | ||
| PCT/US2017/015765 WO2017136315A1 (en) | 2016-02-05 | 2017-01-31 | Aminothiazole compounds and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511564A JP2019511564A (ja) | 2019-04-25 |
| JP2019511564A5 JP2019511564A5 (cg-RX-API-DMAC7.html) | 2019-11-14 |
| JP6883049B2 true JP6883049B2 (ja) | 2021-06-02 |
Family
ID=59496120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560435A Active JP6883049B2 (ja) | 2016-02-05 | 2017-01-31 | アミノチアゾール化合物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10047078B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3411035B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6883049B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102449712B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109069504B (cg-RX-API-DMAC7.html) |
| ES (1) | ES2909612T3 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI620748B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017136315A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3205654T (pt) | 2010-05-20 | 2019-04-22 | Array Biopharma Inc | Compostos macrocíclicos como inibidores de cinases trk |
| EA035049B1 (ru) | 2015-07-16 | 2020-04-22 | Аррэй Байофарма Инк. | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| CA3049136C (en) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| EP3801529B1 (en) | 2018-05-25 | 2023-10-11 | OncoCube Therapeutics LLC | Highly potent tacc3 inhibitor as a novel anticancer drug candidate |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| CN117460724A (zh) * | 2021-04-12 | 2024-01-26 | A2A制药有限公司 | 用于治疗癌症的组合物和方法 |
| KR20250005157A (ko) | 2022-03-24 | 2025-01-09 | 에이2에이 파마수티칼스, 잉크. | 암 치료를 위한 조성물 및 방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2366932C (en) * | 1999-04-15 | 2009-08-25 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| DE60117605T2 (de) * | 2000-12-21 | 2006-12-07 | Bristol-Myers Squibb Co. | Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie |
| CA2503715A1 (en) * | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Kinase inhibitors |
| CN101106990B (zh) * | 2005-01-26 | 2010-12-08 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| EA019289B1 (ru) | 2008-04-21 | 2014-02-28 | Тайджен Байотекнолоджи Ко., Лтд. | Производные аминопиридина, аминопиримидина и амино-1,3,5-триазина |
| WO2010046780A2 (en) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
| JP5765342B2 (ja) | 2010-08-10 | 2015-08-19 | アステラス製薬株式会社 | へテロ環化合物 |
| US9255072B2 (en) * | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
| AP3907A (en) | 2011-09-27 | 2016-11-23 | Novartis Ag | 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
| WO2013143466A1 (zh) * | 2012-03-27 | 2013-10-03 | 广东东阳光药业有限公司 | 作为欧若拉激酶抑制剂的取代嘧啶衍生物 |
-
2017
- 2017-01-26 TW TW106103165A patent/TWI620748B/zh active
- 2017-01-30 US US15/419,183 patent/US10047078B2/en active Active
- 2017-01-31 ES ES17747997T patent/ES2909612T3/es active Active
- 2017-01-31 JP JP2018560435A patent/JP6883049B2/ja active Active
- 2017-01-31 CN CN201780010118.4A patent/CN109069504B/zh active Active
- 2017-01-31 KR KR1020187024997A patent/KR102449712B1/ko active Active
- 2017-01-31 WO PCT/US2017/015765 patent/WO2017136315A1/en not_active Ceased
- 2017-01-31 EP EP17747997.9A patent/EP3411035B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102449712B1 (ko) | 2022-09-30 |
| CN109069504B (zh) | 2022-06-28 |
| EP3411035A4 (en) | 2019-08-14 |
| TWI620748B (zh) | 2018-04-11 |
| US10047078B2 (en) | 2018-08-14 |
| EP3411035B1 (en) | 2022-03-02 |
| EP3411035A1 (en) | 2018-12-12 |
| KR20180132618A (ko) | 2018-12-12 |
| JP2019511564A (ja) | 2019-04-25 |
| WO2017136315A1 (en) | 2017-08-10 |
| HK1258689A1 (zh) | 2019-11-15 |
| TW201728583A (zh) | 2017-08-16 |
| ES2909612T3 (es) | 2022-05-09 |
| US20170226100A1 (en) | 2017-08-10 |
| CN109069504A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6883049B2 (ja) | アミノチアゾール化合物及びその使用 | |
| JP7550205B2 (ja) | Ｎ－（シアノメチル）－４－（２－（４－モルホリノフェニルアミノ）ピリミジン－４－イル）ベンズアミド塩酸塩 | |
| JP7789832B2 (ja) | がんを治療するための組成物及び方法 | |
| JP2022009090A (ja) | 癌を治療するためのｋｒａｓ阻害剤の投与 | |
| TWI484960B (zh) | 嘧啶衍生物 | |
| KR20180017013A (ko) | K-Ras 조절제 | |
| KR20070115879A (ko) | 의학 장애의 치료용 ｃｘｃｒ4 길항제 | |
| JP6979595B2 (ja) | プロテインキナーゼ阻害剤としてのアミノチアゾール化合物 | |
| IL298132A (en) | Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1h-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7h)-one | |
| US20240245634A1 (en) | Pcna inhibitors and egfr inhibitors for cancer treatment | |
| EP3250551B1 (en) | Anti-cancer compounds | |
| TWI691500B (zh) | 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物 | |
| TWI722106B (zh) | 具有抗癌活性之嘌呤化合物 | |
| JP6782710B2 (ja) | Ｒａｃ−ＧＴＰアーゼ媒介性障害を処置するための化合物 | |
| CN113727713B (zh) | 氟取代的2-氨基噻唑-5-芳香族甲酰胺的用途 | |
| CN113727981B (zh) | 激酶抑制剂及其制备、药物组合物和用途 | |
| HK1258689B (en) | Aminothiazole compounds and use thereof | |
| WO2024193509A1 (zh) | 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法 | |
| HK40076454A (en) | Application of fluoro-substituted 2-aminothiazole-5-aromatic carboxamide | |
| CN119841776A (zh) | 酪氨酸激酶抑制剂和其用途 | |
| CN118666846A (zh) | 苯甲羰基吲哚类衍生物及其用途 | |
| HK40042521B (zh) | 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法 | |
| WO2019143833A1 (en) | Compounds for treating rac-gtpase mediated disorder | |
| HK1233924A1 (en) | Derivatives of cephalosporin for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20181106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20181106 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20190709 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190709 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191001 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191001 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200924 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201006 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210105 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210421 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210507 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6883049 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |